title: [Postoperative analgesia with fentanyl combined with flurbiprofen axetil following gynecologic surgery for turnor].
abstract: OBJECTIVE
  a To observe the analgesic effect of fentanyl combined with flurbiprofen axetil for postoperative analgesia after gynecologic surgery.
  
  
  METHODS
  One hundred and forty patients undergoing gynecologic surgery were randomized equally into two groups to receive postoperative patient controlled intravenous analgesia (PCIA) with fentanyl (1.6-1.8 mg) plus tropisetron (5 mg/100 ml) (group I), or with fentanyl (0.8-1.0 mg) and flurbiprofen axetil (200 mg) plus tropisetron (5 mg/100 ml) (group II), at the PCIA rate of 2 ml/h, bolus dose of 1 ml, and lock time of 15 min. At 6 h (T1), 12 h (T2), 24 h (T3), and 48 h (T4) after the operation, the analgesic effect was evaluated with the Prine-Henry score (PHS), and the side effects were recorded. The coagulation function of the patients was assessed with thrombelastography before (T0) and 48 h (T4) after the operation, and the time of gastrointestinal function recovery was recorded.
  
  
  RESULTS
  The fentanyl dose was significantly less in group II than in group I (P<0.05). At the time points of T1 and T2, the PHS in group II was significantly lower than that in group I (P<0.05), but comparable between the two groups at T3 and T4 (P>0.05). Significant higher incidences of the adverse effects such as nausea, dizziness and lethargy was noted in group I than in group II (P<0.05). Compared with that at T0, the parameter K was significantly delayed at T4 in both groups (P<0.05). The two groups showed similar time of gastrointestinal function recovery after the operation (P>0.05).
  
  
  CONCLUSIONS
  Flurbiprofen axetil combined with fentanyl for postoperative analgesia can significantly reduce fentanyl dose and the incidence of adverse effects associated with fentanyl without obviously affecting the coagulation and gastrointestinal functions.
authors.affiliation: Department of Anesthesiology, State Key Laboratory of Oncology of South China, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China. wenqianlin@21cn.com
authors.forename: Wen-qian
authors.initials: WQ
authors.lastname: Lin
authors.forename: Long-hui
authors.initials: LH
authors.lastname: Cao
authors.forename: Zhong-jian
authors.initials: ZJ
authors.lastname: Zhong
authors.forename: Li-li
authors.initials: LL
authors.lastname: Wen
authors.forename: Xiao-hui
authors.initials: XH
authors.lastname: Bai
mesh_terms: D000328:Adult; D000368:Aged; D000701:Analgesics, Opioid / Q000008:administration & dosage; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D004357:Drug Synergism; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage*; D005480:Flurbiprofen / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005833:Genital Neoplasms, Female / Q000601:surgery*; D013509:Gynecologic Surgical Procedures / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged; D010149:Postoperative Pain / Q000188:drug therapy*
chemical_list: D000701:Analgesics, Opioid; D000894:Anti-Inflammatory Agents, Non-Steroidal; D005480:Flurbiprofen; C504422:flurbiprofen axetil; D005283:Fentanyl